Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/20/2017 07/21/2017 07/24/2017 07/25/2017 07/26/2017 Date
62.94(c) 62.63(c) 62.57(c) 62.36(c) 61.8 Last
6 655 095 6 906 447 7 783 692 5 955 856 9 366 722 Volume
+0.51% -0.49% -0.10% -0.34% -0.90% Change
More quotes
Financials ($)
Sales 2017 40 070 M
EBIT 2017 13 715 M
Net income 2017 7 101 M
Debt 2017 3 365 M
Yield 2017 3,01%
Sales 2018 41 314 M
EBIT 2018 14 436 M
Net income 2018 8 736 M
Debt 2018 2 625 M
Yield 2018 3,11%
P/E ratio 2017 23,20
P/E ratio 2018 18,06
EV / Sales2017 4,34x
EV / Sales2018 4,19x
Capitalization 170 565 M
More Financials
Company
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.It operates through the following segments: Pharmaceutical, Animal Health, Alliances and Healthcare Services.The Pharmaceutical... 
Sector
Pharmaceuticals
Calendar
07/28 | 12:45pmEarnings Release
More about the company
Surperformance© ratings of Merck and Company
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK AND COMPANY
07/25 MERCK : Announces Fourth-Quarter 2017 Dividend
07/25MERCK & CO., INC. : half-yearly earnings release
07/25 MERCK : ’s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpo..
07/25 PFIZER : Corning, with assists from Pfizer and Merck, plans $500M pharma glass p..
07/25DJSamsung Enters U.S. Drug Market -- WSJ
07/24 MERCK : Provides Update on Phase 3 Study of KEYTRUDA® (pembrolizumab) Monotherap..
07/24DJSamsung Releases Arthritis Drug in First Foray Into U.S. Pharmaceuticals
07/24DJCorrection to Samsung Drug Story
07/24DJSamsung Releases Lower-Cost Alternative to Johnson & Johnson's Drug Remicade
07/24 MERCK : Announces U.S. Launch of RENFLEXIS™ (infliximab-abda), a Biosimila..
More news
Sector news : Pharmaceuticals - NEC
06:16pDJASTRAZENECA : European Commission Approves Breast Cancer Treatment
05:38pDJGLAXOSMITHKLINE : Glaxo Ditches Raft of R&D Projects to Focus on Best Prospects ..
05:36pDJGLAXOSMITHKLINE : Correction to Glaxo Ditches Raft of R&D Projects Article
03:30pDJGLAXOSMITHKLINE : Glaxo Ditches Raft of R&D Projects to Focus on Best Prospects ..
12:47pDJGLAXOSMITHKLINE : Sharpens R&D, Axes 30 Research Programs
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on MERCK AND COMPANY 
2013A resistance as obstacle
More Strategies
Latest Tweets
06:46p3 Things In Biotech You Should Learn Today: July 26, 2017  
06:33pBMO's Alex Arfaei says there's a good chance $AZN will release MYSTIC top-lin.. 
05:25pMerck, Celgene go beyond the pill with Savor's cancer nutrition programs  
05:15pHow Merck's new cancer blockbuster almost didn't come to be:
8
04:52pThe Startling History Behind Merck's New Cancer Blockbuster: Forbes
2
More tweets
Qtime:213
News from SeekingAlpha
12:46p 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 26, 2017
07/25 Merck declares $0.47 dividend
07/25 ARALEZ : A Quick Overview Of The Investment Thesis
07/25 Samsung Leaps Into Its First U.S. Biosimilars Battle
07/25 Merck's Keynote Falls Flat, And That's Just Fine
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,7 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY5.93%170 565
JOHNSON & JOHNSON14.47%355 263
NOVARTIS7.35%220 651
ROCHE HOLDING LTD.4.30%220 599
PFIZER1.91%197 115
SANOFI7.50%121 268